News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Swedish Orphan Biovitrum Hosts Capital Market Day Event - Announces Phase I Complement Inhibitor Programs


11/5/2013 9:29:32 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Swedish Orphan Biovitrum AB (publ) (Sobi) announced its intention to bring a novel investigational biopharmaceutical drug candidate, SOBI002, into a phase I trial. The company also shared information regarding phase III data for Kepivance® recently acquired from Amgen. These updates as well as expectations for top line data for Kiobrina early next year were provided today at the company's Capital Markets Event in Stockholm.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES